Literature DB >> 10217294

High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.

L W Fitzgerald1, D S Conklin, C M Krause, A P Marshall, J P Patterson, D P Tran, G Iyer, W A Kostich, B L Largent, P R Hartig.   

Abstract

Many modern models of receptor-G protein function assume that there is a direct relationship between high-affinity agonist binding and efficacy. The validity of this assumption has been recently questioned for the serotonin 5-HT2A receptor. We examined the intrinsic activities of various ligands in activating phosphoinositide hydrolysis and measured their respective binding affinities to the high- and low-affinity states of the 5-HT2C (VNV isoform) and 5-HT(2A) receptors. Ligand binding affinities for the high-affinity state of the receptors were determined using 1-(4-[125I]iodo-2,5-dimethoxyphenyl)2-aminopropane, whereas [3H]mesulergine and N-[3H]methylspiperone were used, in the presence of excess guanine nucleotide [guanosine 5'-O-(3-thiotriphosphate)], to define binding to the low-affinity state of the 5-HT2C and 5-HT2A receptors, respectively. Antagonists labeled the high- and low-affinity states of each receptor with comparable affinities. Previously identified inverse agonists of the 5-HT2C receptor behaved as silent antagonists in our systems even when the receptor was overexpressed at a relatively high density. In contrast, the ability of agonists to bind differentially to the high- and low-affinity states of the 5-HT2A and 5-HT2C receptors was highly correlated (r2 = 0.86 and 0.96, respectively) with their intrinsic activities. These data suggest that high-affinity agonist states can account for agonist efficacy at human 5-HT2A or 5-HT2C receptors without the need for considering additional transition or active states of the receptor-ligand complex. The procedure described herein may expedite drug discovery efforts by predicting intrinsic activities of ligands solely from ligand binding assays.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217294     DOI: 10.1046/j.1471-4159.1999.0722127.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

1.  Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptor.

Authors:  J Tracy Alder; Uli Hacksell; Philip G Strange
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 4.  Advances in simultaneous PET/MR for imaging neuroreceptor function.

Authors:  Christin Y Sander; Hanne D Hansen; Hsiao-Ying Wey
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-13       Impact factor: 6.200

5.  Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers.

Authors:  Anders Ettrup; Martin Hansen; Martin A Santini; James Paine; Nic Gillings; Mikael Palner; Szabolcs Lehel; Matthias M Herth; Jacob Madsen; Jesper Kristensen; Mikael Begtrup; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

6.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

7.  Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors.

Authors:  Christopher S Knauer; Jeffrey E Campbell; Christopher L Chio; Lawrence W Fitzgerald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-12-05       Impact factor: 3.000

8.  Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors.

Authors:  Claudio Acuña-Castillo; Claudio Villalobos; Pablo R Moya; Patricio Sáez; Bruce K Cassels; J Pablo Huidobro-Toro
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 9.  Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications.

Authors:  Kelly A Berg; William P Clarke; Kathryn A Cunningham; Umberto Spampinato
Journal:  Neuropharmacology       Date:  2008-06-17       Impact factor: 5.250

10.  LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2009-11-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.